Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Microbiology

Vol 9 No 2 (2024): December

Optimizing Conditions to Combat Antibiotic Resistance in Pathogenic Bacteria
Mengoptimalkan Kondisi untuk Memerangi Resistensi Antibiotik pada Bakteri Patogen



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.9248
Published
July 11, 2024

Abstract

Background: Antimicrobial resistance (AMR) is a significant adaptive trait that allows pathogenic bacterial subpopulations to out-compete and out-survive their microbial neighbors and overcome host defenses. Specific Background: Despite extensive research, the influence of various environmental parameters on antibiotic sensitivity in pathogenic bacteria remains underexplored. Knowledge Gap: There is limited understanding of how temperature, pH, bacterial inoculum volume, and culture medium amount affect the antibiotic resistance of both gram-negative and gram-positive bacteria. Aims: To investigate the effects of these parameters on the antibiotic sensitivity of four standard laboratory strains: Escherichia coli, Proteus spp., Klebsiella spp., and Staphylococcus aureus. Results: Our findings indicate imipenem exhibited the highest sensitivity, with percentages varying significantly based on temperature (92% at 35-39°C), pH (83% at pH 6-8), inoculum volume (42% at 0.1-1.0 μL), and medium volume (67% at 15-35 ml). Conversely, antibiotics such as Piperacillin, Amoxicillin, Erythromycin, Tetracycline 30, and Cephalexin showed high resistance, with Tetracycline 10 being the most resistant. Novelty: This study highlights the significant impact of environmental conditions on bacterial antibiotic resistance, emphasizing the need for tailored antibiotic use based on specific bacterial characteristics and growth conditions. Implications: The results suggest that optimizing environmental parameters can enhance antibiotic efficacy and inform better clinical practices to combat AMR, thus improving treatment outcomes for bacterial infections.

Highlights:

 

  1. Parameter Influence: Temperature, pH, inoculum, medium amount affect antibiotic sensitivity.
  2. Highest Sensitivity: Imipenem most effective across conditions.
  3. Tailored Use: Optimize conditions for better antibiotic efficacy.

 

Keywords: Antimicrobial resistance, bacterial sensitivity, environmental parameters, Imipenem, pathogenic bacteria

References

  1. . P. D. Tamma, S. L. Aitken, R. A. Bonomo, A. J. Mathers, D. van Duin, and C. J. Clancy, "Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)," Clin. Infect. Dis., vol. 75, pp. 187–212, 2022.
  2. . E. Raphael, M. M. Glymour, and H. F. Chambers, "Trends in Prevalence of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolated from Patients with Community- and Healthcare-Associated Bacteriuria: Results from 2014 to 2020 in an Urban Safety-Net Healthcare System," Antimicrob. Resist. Infect. Control, vol. 10, p. 118, 2021.
  3. . A. A. Abdul-Razak, "Effect of Some B-Lactamase Inhibitors and Combined Action of Some Antibiotics on Pseudomonas aeruginosa Resistant to Antibiotics and Some Heavy Metals Isolated from Otitis Media," M.S.C. thesis, Al-Mustansiriya University, Baghdad, Iraq, 2000.
  4. . M. A. Aslam, Z. Ahmed, and R. Azim, "Microbiology and Drug Sensitivity Patterns of Chronic Suppurative Otitis Media," J. Coll. Physicians Surg. Pak., vol. 14, no. 8, pp. 459-461, 2004.
  5. . M. Jamal et al., "Bacterial Biofilm and Associated Infections," J. Chin. Med. Assoc., vol. 81, pp. 7-11, 2018.
  6. . N. Høiby et al., "ESCMID Guideline for the Diagnosis and Treatment of Biofilm Infections 2014," Clin. Microbiol. Infect., vol. 21, pp. S1-S25, 2015.
  7. . K. van Loon, A. F. Voor in 't Holt, and M. C. Vos, "A Systematic Review and Meta-Analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae," Antimicrob. Agents Chemother., vol. 62, no. 1, pp. e01730-17, 2017.
  8. . A. Potron, L. Poirel, and P. Nordmann, "Emerging Broad-Spectrum Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and Epidemiology," Int. J. Antimicrob. Agents, vol. 45, pp. 568-585, 2015.
  9. . C. López-Causapé, G. Cabot, E. Del Barrio-Tofiño, and A. Oliver, "The Versatile Mutational Resistome of Pseudomonas aeruginosa," Front. Microbiol., vol. 9, p. 685, 2018.
  10. . M. S. Attallah, "Microbiology of Chronic Suppurative Otitis Media with Cholesteatoma," Saudi Med. J., vol. 21, no. 10, pp. 924-927, 2000.
  11. . R. M. Atlas, L. C. Parks, and A. E. Brown, Laboratory Manual of Experimental Microbiology, 1st ed., St. Louis: Mosby-Year Book, Inc., 1995.
  12. . Clinical and Laboratory Standards Institute (CLSI), "Performance Standards for Antimicrobial Susceptibility Testing Twenty-Second Informational Supplement," CLSI Document M100-S22, 2018.
  13. . Centers for Disease Control and Prevention (CDC), "Core Elements of Hospital Antibiotic Stewardship Programs," U.S. Department of Health and Human Services, Atlanta, GA, USA, 2019. [Online]. Available: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html [Accessed: Mar. 30, 2023].
  14. . World Health Organization (WHO), "Antimicrobial Resistance: Executive Board 136 / 20, EB136 / 1 of the Provisional Agenda 20," 2014.
  15. . I. V.-M. N. Idalia and F. Bernardo, "Escherichia coli as a Model Organism and Its Application in Biotechnology," Recent Adv. Physiol. Pathog. Biotechnol. Appl. Tech Open Rij., vol. 13, pp. 253–274, 2017.
  16. . E. Denamur, O. Clermont, S. Bonacorsi, and D. Gordon, "The Population Genetics of Pathogenic Escherichia coli," Nat. Rev. Microbiol., vol. 19, pp. 37–54, 2021.
  17. . Antimicrobial Resistance Collaborators, "Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis," Lancet Lond. Engl., vol. 399, pp. 629-655, 2022.
  18. . K. Patel, S. M. Godden, E. E. Royster, B. A. Crooker, T. J. Johnson, E. A. Smith, and S. Sreevatsan, "Prevalence, Antibiotic Resistance, Virulence and Genetic Diversity of Staphylococcus aureus Isolated from Bulk Tank Milk Samples of U.S. Dairy Herds," BMC Genomics, vol. 22, no. 1, p. 367, 2021.
  19. . D. Yahav et al., "Seven versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-Negative Bacteremia: A Noninferiority Randomized Controlled Trial," Clin. Infect. Dis., vol. 69, pp. 1091–1098, 2019.
  20. . L. K. Jennings et al., "Pseudomonas aeruginosa Aggregates in Cystic Fibrosis Sputum Produce Exopolysaccharides That Likely Impede Current Therapies," Cell Rep., vol. 34, 2021.
  21. . B. Cao et al., "Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model," PLoS One, vol. 11, p. e0153616, 2016.
  22. . B. Cao et al., "Antibiotic Penetration and Bacterial Killing in a Pseudomonas aeruginosa Biofilm Model," J. Antimicrob. Chemother., vol. 70, pp. 2057-2063, 2015.
  23. . L. Christophersen et al., "In Vivo Demonstration of Pseudomonas aeruginosa Biofilms as Independent Pharmacological Microcompartments," J. Cyst. Fibros., vol. 19, pp. 996-1003, 2020.
  24. . J. Haagensen et al., "Spatiotemporal Pharmacodynamics of Meropenem- and Tobramycin-Treated Pseudomonas aeruginosa Biofilms," J. Antimicrob. Chemother., vol. 72, pp. 3357-3365, 2017.
  25. . D. Wilmaerts, E. M. Windels, N. Verstraeten, and J. Michiels, "General Mechanisms Leading to Persister Formation and Awakening," Trends Genet., vol. 35, pp. 401-411, 2019.
  26. . D. Martins et al., "Superoxide Dismutase Activity Confers (p)ppGpp-Mediated Antibiotic Tolerance to Stationary-Phase Pseudomonas aeruginosa," Proc. Natl. Acad. Sci. USA, vol. 115, pp. 9797-9802, 2018.
  27. . C. H. Vu et al., "Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections (REDUCE-BSI)," Antimicrob. Steward. Healthc. Epidemiol., vol. 2, p. e39, 2022.
  28. . L. McCarthy, P. Colley, H. L. Nguyen, and M. Berhe, "Impact of Pharmacist Intervention in Response to Automated Molecular Diagnostic Tests of Blood Culture Results," J. Pharm. Pract., vol. 35, pp. 47–53, 2022.

Downloads

Download data is not yet available.